Heartworm Drugs Market

Heartworm Drugs Market Analysis

The Heartworm Drugs Market size is estimated at USD 1.42 billion in 2025, and is expected to reach USD 2.05 billion by 2030, at a CAGR of 7.61% during the forecast period (2025-2030).

Heartworm disease, caused by the parasitic worm Dirofilaria immitis and spread through mosquito bites, is a life-threatening condition that can lead to severe lung damage, organ damage, heart failure, and death in pets. Urban areas are experiencing a significant increase in pet adoptions, which is driving higher demand for veterinary services, particularly heartworm prevention. As pets become integral to households, ensuring their health has emerged as a critical focus for pet owners. According to data published by Shelter Animals Count in 2023 indicates that 6.5 million cats and dogs entered shelters and were rescued across the Americas. Of these, 3.3 million were cats, while the remaining 3.2 million were dogs. The combined adoption rates for these species have shown consistent growth, increasing from 56% of intakes in 2019 to 61% in 2023. Additionally, during the COVID-19 pandemic, nearly 1 in 5 households adopted a pet, as reported by the American Society for the Prevention of Cruelty to Animals. As pet ownership rises, so does the demand for preventive treatments, notably heartworm medications. Increasingly, pet owners recognize the vital role of regular veterinary care in ensuring their pets' health and wellness.

Heartworm disease is becoming more common, especially in areas with warm, humid climates that are ideal for mosquito breeding, as mosquitoes are the primary carriers of heartworm larvae. This has led to a growing need for effective prevention and treatment options to protect pets from this potentially serious condition. Additionally, the increasing incidence of Dirofilaria immitis, the parasite responsible for heartworm disease, is a significant factor driving the growth of the heartworm drugs market. As more pets are diagnosed with heartworm disease, the demand for effective prevention and treatment options continues to rise. For example, The Companion Animal Parasite Council reported nearly 66,000 confirmed heartworm cases in dogs across the United States in 2023, with Michigan alone accounting for over 1,500 cases during the same year.

Furthermore, increasing efforts by industry stakeholders to enhance awareness regarding heartworm-related issues in animals are driving market growth. For instance, according to data published by the American Veterinary Medical Association in October 2024, the American Heartworm Society (AHS) conducts a survey every three years to analyze reporting clinics and the overall dog population. Each survey has consistently shown an increase of over 50,000 in the number of dogs testing positive for heartworm.

However, the high cost of heartworm drugs, side effects and safety concerns of heartworm drugs restrain the market growth.

Heartworm Drugs Market Trends

Macrocyclic Lactones Segment is Expected to Witness Significant Growth Over the Forecast Period

acrocyclic lactones, including well-known compounds such as ivermectin, selamectin, and moxidectin, are widely preferred for heartworm prevention and treatment due to their high efficacy and safety profile. These drugs eliminate the third- and fourth-stage larvae of Dirofilaria immitis, the nematode responsible for heartworm disease, preventing the larvae from maturing into adult worms that can migrate to the heart and lungs. Owing to their proven efficacy and safety, the macrocyclic lactones segment is projected to register significant growth throughout the forecast period. For instance, ivermectin is a well-known product in popular brands like Heartgard, specifically formulated for dogs to prevent heartworm disease. For instance, a study published by Parasites & Vectors in 2022 revealed that adult heartworms were detected in all dogs treated with Heartgard Plus or Interceptor Plus, demonstrating preventive efficacies of 37.7% and 34.9%, respectively. Similarly, products such as Advantage Multi, which contains moxidectin, are used not only to prevent heartworms but also to treat other parasitic infections, including fleas, ticks, and intestinal worms.

Additionally, veterinarians widely recommend these drugs due to their proven effectiveness and reliability in preventing heartworm disease. For instance, the MSD Manual of 2023 highlights that treating heartworm infections typically involves administering melarsomine, an organic arsenic compound, through intramuscular injections in a three-dose regimen. Additionally, the chronic use of specific macrocyclic lactones combined with doxycycline has proven effective in cases where melarsomine is unavailable or unsuitable. This combined approach ensures effective management of heartworm disease, even in advanced cases.

Asia Pacific is Expected to Dominate the Heartworm Drugs Market

Asia Pacific is projected to lead the market, driven by a substantial pet population and growing heartworm disease awareness. For example, as per 2024 data published by Dogster, over 11% of the Indian population is estimated to own at least four pets per household. Additionally, an article of Parasite & Vectors published in February 2023, states that prior to the implementation of macrocyclic lactones, the prevalence of dirofilariosis in Queensland, Australia, was reported to be significantly high, reaching a rate of approximately 90%. This highlights the critical need for effective preventive measures in managing the spread of the disease within the region.

The region also benefits from the strategic initiatives of major global pharmaceutical companies like Merck Animal Health, Zoetis, and Elanco, which have strengthened their presence in these markets. These companies are actively engaged in raising awareness among pet owners about heartworm prevention and enhancing the availability of heartworm drugs. For instance, in June 2023, Zoetis collaborated with Adopt a Pet to announce the recipients of their Shelter Grant. This initiative supports over 20 animal welfare organizations by providing essential medications, including vaccines, antibiotics, and FTH products, to ensure proper care for cats and dogs prior to adoption.

Therefore, owing to the factors mentioned above, the growth of the market studied is anticipated in the Asia Pacific region.

Heartworm Drugs Industry Overview

The heartworm drugs Market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold significant market share and are well known include Boehringer Ingelheim International GmbH, Elanco Animal Health, Zoetis Inc., Merck & Co., Inc., Virbac Corporation, Bayer Animal Health, Ceva Animal Health, LLC, Vetoquinol S.A., Dechra Pharmaceuticals PLC, Norbrook among others.

Heartworm Drugs Market Leaders

Heartworm Drugs Market News

• October 2024: Elanco received FDA approval for Credelio Quattro. Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is a groundbreaking oral parasiticide for dogs, offering comprehensive protection against six parasites. This includes fleas, ticks, heartworms, roundworms, hookworms, and three distinct species of tapeworms, addressing coverage gaps left by other brands. By providing an all-in-one solution, Credelio Quattro sets a new standard in canine parasite prevention, ensuring enhanced convenience and effectiveness for pet owners.
• July 2023: Boehringer Ingelheim secured FDA approval for NexGard Plus, a monthly beef-flavored soft chew designed to provide comprehensive protection for dogs against fleas, ticks, heartworm disease, roundworms, and hookworms. By integrating both internal and external parasite prevention into a single, palatable chew, NexGard PLUS enhances monthly compliance, making it convenient and enjoyable for both pets and their owners.